Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | EDNRB | P24530 | 1/20 | 0.32 |
| ▸ | EDNRA | P25101 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 3/20 | 0.31 |
| ▸ | PPARA | Q07869 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8170659 | 0.82 | TBXAS1 (0.41) | KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL6446028 | 0.80 | KMT2A (0.43) | KMT2AMEN1CYP2D6BLMFDPS | |
| SCHEMBL5325316 | 0.76 | SMN1; SMN2 (0.43) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL8188378 | 0.75 | KMT2A (0.46) | KMT2AMEN1CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL6027451 | 0.74 | FDPS (0.41) | KMT2AMEN1FDPSALDH1A1 | |
| SCHEMBL2852162 | 0.74 | KMT2A (0.40) | KMT2AMEN1CYP2D6BLMFDPS | |
| SCHEMBL8806580 | 0.73 | KMT2A (0.44) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL7971128 | 0.72 | ALDH1A1 (0.43) | KMT2AMEN1CYP2D6BLMALDH1A1 | |
| SCHEMBL647893 | 0.72 | KMT2A (0.46) | KMT2AMEN1CYP2D6BLMFDPS | |
| SCHEMBL5319750 | 0.72 | MEN1 (0.41) | KMT2AMEN1CYP2D6BLMFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9840730-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2017-12-12 | — | — | US | disclosed |
| EP-2635582-B1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | PROMEGA CORP (US) | 2016-01-27 | — | — | EP | disclosed |
| US-20160002703-A1 | IMIDAZO[1,2-alpha]PYRAZINE DERIVATIVES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2016-01-07 | — | — | US | disclosed |
| US-9139836-B2 | Imidazo[1,2-a]pyrazine derivatives | PROMEGA CORPORATION (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150064731-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2015-03-05 | — | — | US | disclosed |
| US-8809529-B2 | Imidazo[1,2-α]pyrazine derivatives | PROMEGA CORPORATION (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140227759-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140223590-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | Promego Corporation (US) | 2014-08-07 | — | — | US | disclosed |
| US-8669103-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2014-03-11 | — | — | US | disclosed |
| WO-2012061530-A2 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORPORATION (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012061529-A1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | PROMEGA CORPORATION (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002703-A1 | IMIDAZO[1,2-alpha]PYRAZINE DERIVATIVES | GLB1, NISCH, BOLA2; BOLA2B | KMT2A 3183/4885MEN1 1366/4885CYP2D6 802/4885 |
| US-20150064731-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | GLB1, LUC7L2, GUSB | KMT2A 2786/4885MEN1 2343/4885CYP2D6 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.